Wicab is a pioneering medical device company commercializing neuroplasticity-based sensory substitution technology. Its flagship product, the BrainPort Vision Pro, is an FDA-cleared, non-surgical prescription device that translates visual information into electrotactile signals on the tongue, allowing the brain to interpret spatial information. The company also markets the BrainPort Balance Plus for vestibular rehabilitation and holds an ISO 13485 certification, with products available in the US, EU, Canada, and other regions. Wicab's work is grounded in decades of neuroscience research from its founder, Dr. Paul Bach-y-Rita.
Sensory substitution technology using electrotactile stimulation on the tongue to transmit spatial information from digital sensors (e.g., camera, accelerometer) to the brain, leveraging neuroplasticity.
Opportunities
Expanding insurance reimbursement for the BrainPort Vision Pro is a major near-term opportunity that could dramatically increase patient access.
The large and growing market for balance disorder treatments, particularly in the aging population, presents a significant secondary growth channel for the Balance Plus device.
The core sensory substitution platform also holds potential for future application in other neurological rehabilitation areas, such as motor control for stroke or spinal cord injury patients.
Risk Factors
Market adoption is constrained by the need for extensive user training and the challenge of securing consistent insurance reimbursement.
The company faces competition from rapidly evolving alternative technologies in visual prosthetics (e.g., retinal implants, gene therapy) and balance therapies.
As a small private firm, Wicab has execution risks related to scaling its commercial operations and funding further clinical development.
Competitive Landscape
In vision assistance, Wicab competes with traditional aids (canes, guide dogs), electronic travel aids (like ultrasonic sensors), and more invasive surgical approaches like retinal implants (e.g., Argus II from Second Sight) and emerging cortical implants. For balance, competitors include vestibular physical therapy protocols, other balance training devices, and implantable vestibular prosthetics. Wicab's key differentiation is its non-invasive, neuroplasticity-based approach that does not require surgery.
